New direct oral anticoagulants (NOAC) - solutions to potential problems with coagulation assessment

Abstract

An overview of the options for laboratory monitoring of the new oral anticoagulants (the direct Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran), and selection of appropriate coagulation tests that can be used in clinical practice are presented.

Keywords

• apixaban
• dabigatran
• laboratory tests
• Rivaroxaban
• emergency medicine